Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN632 in Pediatric Relapsed/Refractory Leukemia
NCT05320380Phase 2Withdrawn
- Sponsor
- Children's Oncology Group
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
01
Overview
A Phase 2 trial of pivekimab sunirine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Planned start Aug 2023; status: withdrawn.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05320380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320380.